Reata Pharmaceuticals, Inc.
(NASDAQ : RETA)

( )
RETA PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson -0.54%164.480.7%$1029.24m
MRKMerck & Co., Inc. 0.29%75.670.7%$923.27m
LLYEli Lilly & Co. -1.08%223.651.1%$922.88m
PFEPfizer Inc. -0.15%39.570.9%$892.93m
ABBVAbbVie, Inc. 0.42%115.881.9%$754.48m
BMYBristol-Myers Squibb Co. 0.16%67.401.0%$615.55m
AZNAstraZeneca Plc 0.14%58.841.2%$402.80m
ANVSAnnovis Bio, Inc. -3.11%86.090.0%$285.45m
NOVNNovan, Inc. -11.93%15.285.8%$192.66m
NVSNovartis AG 0.35%93.920.2%$178.32m
GSKGlaxoSmithKline Plc 0.20%40.570.2%$154.90m
VTRSViatris, Inc. -2.11%15.300.0%$111.82m
BTXBrooklyn ImmunoTherapeutics, Inc. -1.64%14.9712.4%$102.64m
CNSTConstellation Pharmaceuticals, Inc. 0.09%33.730.0%$101.49m
RETAReata Pharmaceuticals, Inc. -0.58%142.593.1%$88.65m

Company Profile

Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by W. Christian Wigley, Waldemar Priebe, Philip J. Thomas, Jef Karel de Brabander, Thomas C. Sudhof, Jonathan M. Graff, and J. Warren Huff in 2002 and is headquartered in Irving, TX.